Multicenter Quantitative and Qualitative Study of the Determinants of Participation in a Cytomegalovirus Preventive Vaccine Study in France in Women Aged 18 to 40 Years Old.
Launched by CENTRE HOSPITALIER UNIVERSITAIRE DE SAINT ETIENNE · Jul 15, 2024
Trial Information
Current as of June 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is looking to understand why women aged 18 to 40 might choose to participate in a study for a vaccine that protects against Cytomegalovirus (CMV). CMV can cause serious health issues in babies, so many women may be motivated to join a trial to help prevent this. The researchers want to see if women feel differently about participating in a vaccine study when it’s aimed at protecting them personally, rather than just for future children. By learning more about the thoughts and feelings of women in this age group, the study hopes to improve how future vaccine trials are designed and how participants are recruited.
To be eligible for this trial, women must be between 18 and 40 years old and currently involved in the CMVCTORY vaccine trial. The study is not yet recruiting participants, but when it begins, women can expect to share their opinions and experiences related to vaccine trials. This feedback will be valuable in shaping better recruitment strategies for future studies in infectious diseases and vaccination. If you're interested or have questions, it’s a great idea to talk to your healthcare provider for more information.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Womens between 18 to 40 included in CMVCTORY vaccine trial
- Exclusion Criteria:
- • Refusal
About Centre Hospitalier Universitaire De Saint Etienne
The Centre Hospitalier Universitaire (CHU) de Saint-Étienne is a leading academic medical center in France, dedicated to advancing healthcare through innovative clinical research and high-quality patient care. With a robust infrastructure that supports a wide range of medical specialties, CHU de Saint-Étienne fosters collaboration between healthcare professionals, researchers, and academic institutions. The center is committed to conducting rigorous clinical trials that adhere to ethical standards and regulatory requirements, aiming to improve treatment outcomes and enhance the overall health of the community. Through its dedication to scientific excellence and patient-centered care, CHU de Saint-Étienne plays a pivotal role in the advancement of medical knowledge and the development of new therapeutic interventions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Saint étienne, , France
Patients applied
Trial Officials
Nelly JACQUEMET, nurse
Principal Investigator
CHU SAINT-ETIENNE
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported